Efficacy Study of IL-21 to Treat Metastatic Melanoma

Inclusion Criteria: * Histologically confirmed surgically incurable metastatic melanoma * Patients must have measurable disease * ECOG performance status of 0 or 1 * Expected life expectancy at least 4 months Exclusion Criteria: * History of and signs/symptoms of uncontrolled brain metastases or edema. * Previous treatment with chemotherapy or any biological anti-cancer drug (prior adjuvant therapy with interferon-alpha is permitted as long as treatment was completed at least six months prior to study entry.) * Radiotherapy: Radiation therapy within 4 weeks prior to entering the study. * Receipt of any investigational drug for treatment of metastatic melanoma prior to this trial.